Furthermore, pre‐vaccination with GRA4 deficient ME49Δompdc could further improve the anti‐tumor effect of ME49Δompdc by triggering stronger IFN‐I and inducing CD64+MAR‐1+CD11b+ DCs that are exceptionally activated in generating potent T cell responses producing IFN‐γ, which slows down and even completely inhibits tumor growth. The gene discussed is IFNG; the disease is neoplasm.